Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.40 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.33 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965332 | 0.85 | CACNB4 (0.46) | ALDH1A1MCHR1CACNB4CACNA1ACACNA1G | |
| SCHEMBL3495599 | 0.85 | GRM2 (0.41) | SPHK1RXFP1 | |
| SCHEMBL3496696 | 0.85 | GRM2 (0.41) | SPHK1RXFP1 | |
| SCHEMBL4962127 | 0.84 | CACNB4 (0.36) | ALDH1A1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL13311238 | 0.83 | KCNH2 (0.39) | RXFP1MCHR1CACNB4CACNA1ACACNA1G | |
| SCHEMBL4964868 | 0.82 | CYP19A1 (0.39) | ALDH1A1CNR2LMNAMEN1KMT2A | |
| SCHEMBL3494723 | 0.82 | MCHR1 (0.39) | ENPP2RXFP1ALDH1A1MCHR1CACNB4 | |
| SCHEMBL3495130 | 0.81 | KMT2A (0.43) | ENPP2ALDH1A1MCHR1CACNB4CACNA1A | |
| SCHEMBL3494652 | 0.80 | CACNB4 (0.40) | ALDH1A1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3496066 | 0.80 | CACNB4 (0.40) | ENPP2ALDH1A1MCHR1CACNB4CACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | claimed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | SPHK1 3826/4885SPHK2 4218/4885VEGFA 4480/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | SPHK1 3826/4885SPHK2 4218/4885VEGFA 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.